Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?

被引：1

作者：

Breccia, Massimo ^{[1
]}

Alimena, Giuliana ^{[1
]}

机构：

[1] Univ Roma La Sapienza, Dept Biotechnol & Hematol, Rome, Italy

来源：

LEUKEMIA RESEARCH | 2009年 / 33卷 / 11期

关键词：

Chronic myeloid leukemia; Prognostic factors; Imatinib; MOLECULAR RESPONSES; INTERFERON-ALPHA; MECHANISMS; DISEASE; BIOLOGY;

D O I：

10.1016/j.leukres.2009.06.022

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1450 / 1451

页数：2

共 15 条

[1] Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet [J].

Baccarani, Michele ;

Saglio, Giuseppe ;

Goldman, John ;

Hochhaus, Andreas ;

Simonsson, Bengt ;

Appelbaum, Frederick ;

Apperley, Jane ;

Cervantes, Francisco ;

Cortes, Jorge ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Frangois ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Niederwieser, Dielger ;

Silver, Richard ;

Hehlmann, Rudiger .

BLOOD, 2006, 108 (06) :1809-1820

[2]

CORTES JE, 2009, LEUKEMIA 0430

[3] Translation of the Philadelphia chromosome into therapy for CML [J].

Druker, Brian J. .

BLOOD, 2008, 112 (13) :4808-4817

[4] Chronic myelogenous leukemia: Biology and therapy [J].

Faderl, S ;

Talpaz, M ;

Estrov, Z ;

Kantarjian, HM .

ANNALS OF INTERNAL MEDICINE, 1999, 131 (03) :207-219

[5] Mechanisms of disease - Chronic myeloid leukemia - Advances in biology and new approaches to treatment [J].

Goldman, JM ;

Melo, JV .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (15) :1451-1464

[6] Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia [J].

Hughes, TP ;

Kaeda, J ;

Branford, S ;

Rudzki, Z ;

Hochhaus, A ;

Hensley, ML ;

Gathmann, I ;

Bolton, AE ;

van Hoomissen, IC ;

Goldman, JM ;

Radich, JP ;

Taylor, K ;

Durrant, S ;

Schwarer, A ;

Joske, D ;

Seymour, J ;

Grigg, A ;

Ma, D ;

Arthur, C ;

Bradstock, K ;

Joshua, D ;

Lechner, K ;

Verhoef, G ;

Louwagie, A ;

Martiat, P ;

Straetmans, N ;

Bosly, A ;

Shepherd, J ;

Shustik, C ;

Lipton, J ;

Kovacs, DM ;

Turner, AR ;

Nielsen, JL ;

Birgens, H ;

Bjerrum, OW ;

Guilhot, F ;

Reiffers, J ;

Rousselot, P ;

Facon, T ;

Harousseau, JL ;

Tulliez, M ;

Guerci, A ;

Blaise, D ;

Maloisel, F ;

Michallet, M ;

Fischer, T ;

Hossfeld, D ;

Mertelsmann, R ;

Andreesen, R ;

Nerl, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (15) :1423-1432

[7]

HUGHES TP, 2008, BLOOD, V112

[8] Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α [J].

Merx, K ;

Müller, MC ;

Kreil, S ;

Lahaye, T ;

Paschka, P ;

Schoch, C ;

Weisser, A ;

Kuhn, C ;

Berger, U ;

Gschaidmeier, H ;

Hehlmann, R ;

Hochhaus, A .

LEUKEMIA, 2002, 16 (09) :1579-1583

[9] Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha.: Low levels of residual disease are associated with continuous remission [J].

Paschka, P ;

Müller, MC ;

Merx, K ;

Kreil, S ;

Schoch, C ;

Lahaye, T ;

Weisser, A ;

Petzold, A ;

König, H ;

Berger, U ;

Gschaidmeier,HH ;

Hehlmann, R ;

Hochhaus, A .

LEUKEMIA, 2003, 17 (09) :1687-1694

[10] Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia [J].

Picard, Stephane ;

Titier, Karine ;

Etienne, Gabriel ;

Teilhet, Ernmanuelle ;

Ducint, Dominique ;

Bernard, Marie-Agnes ;

Lassalle, Regis ;

Marit, Gerald ;

Reiffers, Josy ;

Begaud, Bernard ;

Moore, Nicholas ;

Molimard, Mathieu ;

Mahon, Francois-Xavier .

BLOOD, 2007, 109 (08) :3496-3499

← 1 2 →